Literature DB >> 25392187

Testosterone treatment of men with mild cognitive impairment and low testosterone levels.

M M Cherrier1, K Anderson2, J Shofer3, S Millard3, A M Matsumoto4.   

Abstract

INTRODUCTION: This study investigated the effects of testosterone (T) treatment on cognition, mood, and quality of life in men with mild cognitive impairment (MCI) and low serum T levels.
METHODS: A total of 351 community-dwelling men were screened, and 37 men evidenced both MCI and low T of whom 27 agreed for further screening. Twenty-two met all the study inclusion/exclusion criteria and enrolled in a 6-month randomized, double-blind, placebo-controlled study.
RESULTS: Total T levels significantly increased in the T treatment group. No significant changes were observed in measures of cognition, mood, or quality of life other than improvement in 1 objective measure of verbal memory (P < .05) and decreased depression symptoms (P < .02) in the treatment group.
CONCLUSIONS: Testosterone treatment may modestly improve verbal memory and depression symptoms in men with both MCI and low T.
© The Author(s) 2014.

Entities:  

Keywords:  cognition; low serum testosterone; mild cognitive impairment; quality of life; testosterone treatment; verbal memory

Mesh:

Substances:

Year:  2014        PMID: 25392187     DOI: 10.1177/1533317514556874

Source DB:  PubMed          Journal:  Am J Alzheimers Dis Other Demen        ISSN: 1533-3175            Impact factor:   2.035


  16 in total

Review 1.  Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels.

Authors:  Ronald S Swerdloff; Robert E Dudley; Stephanie T Page; Christina Wang; Wael A Salameh
Journal:  Endocr Rev       Date:  2017-06-01       Impact factor: 19.871

2.  Testosterone replacement and improved memory.

Authors:  Corey Lyon; Alicia Wong; Kristen DeSanto
Journal:  Can Fam Physician       Date:  2021-01       Impact factor: 3.275

3.  Cognitive and neurobehavioral symptoms in patients with non-metastatic prostate cancer treated with androgen deprivation therapy or observation: A mixed methods study.

Authors:  Lisa M Wu; Molly L Tanenbaum; Marcel P J M Dijkers; Ali Amidi; Simon J Hall; Frank J Penedo; Michael A Diefenbach
Journal:  Soc Sci Med       Date:  2016-03-17       Impact factor: 4.634

Review 4.  Sex differences in hippocampal area CA3 pyramidal cells.

Authors:  Helen E Scharfman; Neil J MacLusky
Journal:  J Neurosci Res       Date:  2017-01-02       Impact factor: 4.164

Review 5.  Evaluating the beneficial effects of dietary restrictions: A framework for precision nutrigeroscience.

Authors:  Kenneth A Wilson; Manish Chamoli; Tyler A Hilsabeck; Manish Pandey; Sakshi Bansal; Geetanjali Chawla; Pankaj Kapahi
Journal:  Cell Metab       Date:  2021-09-22       Impact factor: 31.373

Review 6.  The Potential of Gonadal Hormone Signalling Pathways as Therapeutics for Dementia.

Authors:  X Du; R A Hill
Journal:  J Mol Neurosci       Date:  2016-08-15       Impact factor: 3.444

7.  Treatment of Men for "Low Testosterone": A Systematic Review.

Authors:  Samantha Huo; Anthony R Scialli; Sean McGarvey; Elizabeth Hill; Buğra Tügertimur; Alycia Hogenmiller; Alessandra I Hirsch; Adriane Fugh-Berman
Journal:  PLoS One       Date:  2016-09-21       Impact factor: 3.240

8.  Systemic inflammation and symptomatology in patients with prostate cancer treated with androgen deprivation therapy: Preliminary findings.

Authors:  Aasha I Hoogland; Heather S L Jim; Brian D Gonzalez; Brent J Small; Danielle Gilvary; Elizabeth C Breen; Julienne E Bower; Mayer Fishman; Babu Zachariah; Paul B Jacobsen
Journal:  Cancer       Date:  2020-12-30       Impact factor: 6.860

9.  Testicular responses to hCG stimulation at varying doses in men with spinal cord injury.

Authors:  W A Bauman; M F La Fountaine; C M Cirnigliaro; S C Kirshblum; A M Spungen
Journal:  Spinal Cord       Date:  2017-02-21       Impact factor: 2.772

10.  The Effects of Testosterone Supplementation on Cognitive Functioning in Older Men.

Authors:  Eka J Wahjoepramono; Prita R Asih; Vilia Aniwiyanti; Kevin Taddei; Satvinder S Dhaliwal; Stephanie J Fuller; Jonathan Foster; Malcolm Carruthers; Giuseppe Verdile; Hamid R Sohrabi; Ralph N Martins
Journal:  CNS Neurol Disord Drug Targets       Date:  2016       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.